JPRN-jRCT2080220871未知2 期
A phase II/III study of SYR-322 in subject with diabetes
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •The subject who is capable of providing consent to participate in this study, with ability to read and understand the informed consent form and other written information, etc.
排除标准
- •1.The subject with serious cardiac disease, cerebrovascular disorder, or serious pancreatic or hematological disease, etc.
- •2.The subject who is considered ineligible to participate in the study by the investigator or subinvestigator, etc.
研究者
相似试验
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-jRCT2080220606Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineJPRN-jRCT2080220568Takeda Pharmaceutical Company Limited240
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a ThiazolidineType 2 diabetes mellitusJPRN-UMIN000001382Takeda Pharmaceutical Company Limited240
未知
3 期
ong-term study of SYR-322Type 2 Diabetes mellitusJPRN-jRCT2080221603TAKEDA PHARMACEUTICAL COMPANY LTD.